Hamidreza Yazdi1, Mitchell R Klement2, Mohammed Hammad2, Daisuke Inoue3, Chi Xu4, Karan Goswami2, Javad Parvizi2. 1. Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA; Department of Orthopaedic Surgery, Iran University of Medical Sciences, Tehran, Iran. 2. Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA. 3. Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA; Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan. 4. Rothman Orthopaedic Institute at Thomas Jefferson University, Philadelphia, PA; Department of Orthopaedic Surgery, General Hospital of People's Liberation Army, Beijing, People's Republic of China.
Abstract
BACKGROUND: Previous studies have demonstrated preoperative anemia to be a strong risk factor for periprosthetic joint infection (PJI) in total joint arthroplasty (TJA). Allogeneic blood transfusion can be associated with increased risk of PJI after primary and revision TJA. Tranexamic acid (TXA) is known to reduce blood loss and the need for allogeneic blood transfusion after TJA. The hypothesis of this study is that administration of intravenous TXA would result in a reduction in PJI after TJA. METHODS: An institutional database was utilized to identify 6340 patients undergoing primary TJA between January 1, 2013 and June 31, 2017 with a minimum of 1-year follow-up. Patients were divided into 2 groups based on whether they received intravenous TXA prior to TJA or not. Patients who developed PJI were identified. All PJI patients met the 2018 International Consensus Meeting definition for PJI. A multivariate regression analysis was performed to identify variables independently associated with PJI. RESULTS: Of the patients included, 3683 (58.1%) received TXA and 2657 (41.9%) did not. The overall incidence of preoperative anemia was 16%, postoperative blood transfusion 1.8%, and PJI 2.4%. Bivariate analysis showed that patients who received TXA were significantly at lower odds of infection. After adjusting for all confounding variables, multivariate regression analysis showed that TXA is associated with reduced PJI after primary TJA. CONCLUSION: TXA can help reduce the rate of PJI after primary TJA. This protective effect is likely interlinked to reduction in blood loss, lower need for allogeneic blood transfusion, and issues related to immunomodulation associated with blood transfusion.
BACKGROUND: Previous studies have demonstrated preoperative anemia to be a strong risk factor for periprosthetic joint infection (PJI) in total joint arthroplasty (TJA). Allogeneic blood transfusion can be associated with increased risk of PJI after primary and revision TJA. Tranexamic acid (TXA) is known to reduce blood loss and the need for allogeneic blood transfusion after TJA. The hypothesis of this study is that administration of intravenous TXA would result in a reduction in PJI after TJA. METHODS: An institutional database was utilized to identify 6340 patients undergoing primary TJA between January 1, 2013 and June 31, 2017 with a minimum of 1-year follow-up. Patients were divided into 2 groups based on whether they received intravenous TXA prior to TJA or not. Patients who developed PJI were identified. All PJI patients met the 2018 International Consensus Meeting definition for PJI. A multivariate regression analysis was performed to identify variables independently associated with PJI. RESULTS: Of the patients included, 3683 (58.1%) received TXA and 2657 (41.9%) did not. The overall incidence of preoperative anemia was 16%, postoperative blood transfusion 1.8%, and PJI 2.4%. Bivariate analysis showed that patients who received TXA were significantly at lower odds of infection. After adjusting for all confounding variables, multivariate regression analysis showed that TXA is associated with reduced PJI after primary TJA. CONCLUSION:TXA can help reduce the rate of PJI after primary TJA. This protective effect is likely interlinked to reduction in blood loss, lower need for allogeneic blood transfusion, and issues related to immunomodulation associated with blood transfusion.
Authors: Pier Francesco Indelli; F Iannotti; A Ferretti; R Valtanen; P Prati; D Pérez Prieto; N P Kort; B Violante; N R Tandogan; A Schiavone Panni; G Pipino; M T Hirschmann Journal: Knee Surg Sports Traumatol Arthrosc Date: 2021-09-13 Impact factor: 4.342
Authors: Chen Changjun; Zhao Xin; Luo Yue; Zhao Chengcheng; Wang Qiuru; Li Qianhao; Kang Pengde Journal: Int Orthop Date: 2021-08-18 Impact factor: 3.075
Authors: Shahid Miangul; Timothy Oluwaremi; Joe El Haddad; Maamoun Adra; Nathan Pinnawala; Hayato Nakanishi; Reem H Matar; Christian A Than; Thomas M Stewart Journal: Eur J Orthop Surg Traumatol Date: 2022-09-26
Authors: Antonio Benjumea; Marta Díaz-Navarro; Rama Hafian; Emilia Cercenado; Mar Sánchez-Somolinos; Javier Vaquero; Francisco Chana; Patricia Muñoz; María Guembe Journal: Front Microbiol Date: 2022-06-30 Impact factor: 6.064
Authors: Antonio Benjumea; Marta Díaz-Navarro; Rama Hafian; Mar Sánchez-Somolinos; Javier Vaquero; Francisco Chana; Patricia Muñoz; María Guembe Journal: Microbiol Spectr Date: 2022-02-16
Authors: Ali Torkaman; Amir Rostami; Mohammad Reza Sarshar; Hossein Akbari Aghdam; Paniz Motaghi; Hamidreza Yazdi Journal: Arch Bone Jt Surg Date: 2020-05
Authors: David A Kolin; Michael A Moverman; Mariano E Menendez; Nicholas R Pagani; Richard N Puzzitiello; Joseph J Kavolus Journal: J Orthop Date: 2021-07-13